Cerulean Pharma has commenced a Phase II study of advanced gastric cancer drug CRLX101 by dosing the first patient.

The investigational anti-cancer agent, CRLX101, is designed to concentrate in tumours and release camptothecin over an extended period of time, prolonging drug exposure at the site of action.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Cerulean chief medical officer Dr Edward Garmey said; "We are fortunate to have another opportunity to collaborate with Drs Yen and Davis to further elucidate the tumour-targeting mechanism of nanopharmaceuticals and to potentially address the significant unmet medical need in gastric cancer."

"The investigational anti-cancer agent, CRLX101, is designed to concentrate in tumours and release camptothecin over an extended period of time, prolonging drug exposure at the site of action."

The trial will assess the activity of CRLX101, a nanopharmaceutical dual inhibitor of topoisomerase 1 and hypoxia-inducible factor-1 alpha, in HER-2 negative gastric cancer patients with progressed disease subsequent to the standard frontline therapy.

Post-dosing tumour biopsies will assist in determining if CRLX101 is localised to human gastric tumour tissue.

See Also:

The study is being conducted at City of Hope Comprehensive Cancer Center, Los Angeles, California.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

City of Hope molecular pharmacology chair and study principal investigator Dr Yen said; "Despite promising advances in the continuing development of HER2-targeted therapies, the majority of gastric cancers are HER2 non-overexpressing, so new therapies are needed."

As a part of the Cerulean’s CRLX101 clinical development programme, a randomised Phase II study conducted in 150 advanced non-small cell lung cancer patients is also being undertaken.